The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological study

Basit Öğe Kaydı
dc.authoridBALCI, Mehmet Ali/0000-0003-0597-7788;
dc.authorwosidBALCI, Mehmet Ali/M-7089-2015
dc.authorwosidtsokos, george C/O-3360-2013
dc.contributor.authorPamuk, O. N.
dc.contributor.authorBalci, M. A.
dc.contributor.authorDonmez, S.
dc.contributor.authorTsokos, G. C.
dc.date.accessioned2024-06-12T11:15:57Z
dc.date.available2024-06-12T11:15:57Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground We estimated the prevalence and incidence, clinical features, treatment, and prognosis of systemic lupus erythematosus (SLE) patients in the Thrace region of Turkey. Methods We retrospectively evaluated 331 patients (307 female, 24 male, mean age 38.5 years) diagnosed with SLE between 2003 and 2014. Clinical features, treatments, and response to various treatment modalities were recorded. Our hospital has been the only tertiary referral center for rheumatological diseases for a mixed rural and urban population of 620,477 people (306,036 females, 314,411 males) for more than 16 years. Results The mean annual incidence of SLE was 4.44/100,000 (females, 8.4/100,000; males, 0.6/100,000). The overall prevalence of SLE was 51.7/100,000 (females, 97.7/100,000; males, 7/100,000). Major organ involvement was present in the following percentages: neurologic involvement: 20.1%; renal involvement: 28.2%; autoimmune hemolytic anemia: 9.6%; thrombocytopenia: 14.7%. Seventeeen SLE patients (13 females, four males) died at a median follow-up of 48 months. The five-year survival was 94.5%, and the ten-year survival was 89.9%. According to Kaplan-Meier survival analysis, poor prognostic factors were: male gender (p=0.015); smoking (p=0.02); pleural involvement (p=0.011); thrombocytopenia (p=0.021); myocarditis (p=0.028); renal involvement (p=0.037); treatment with cyclophosphamide (p=0.011); and an initial high SLEDAI score (>4) (p=0.02). Lymphopenia at the time of diagnosis appeared as a favorable prognostic factor (p=0.008). Cox regression analysis revealed myocarditis (OR: 20.4, p=0.018) and age at diagnosis (OR: 1.11, p=0.035) to be poor, and lymphopenia at the time of diagnosis to be good prognostic factors (OR:0.13, p=0.031). Conclusions The annual incidence and prevalence of SLE in the Thrace region of Turkey is lower than those reported in North America, however they are similar to those reported for European countries. Clinical manifestations appear to be milder, whereas survival was similar to those recorded in Western countries.en_US
dc.identifier.doi10.1177/0961203315603141
dc.identifier.endpage109en_US
dc.identifier.issn0961-2033
dc.identifier.issn1477-0962
dc.identifier.issue1en_US
dc.identifier.pmid26345673en_US
dc.identifier.scopus2-s2.0-84951275875en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage102en_US
dc.identifier.urihttps://doi.org/10.1177/0961203315603141
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24135
dc.identifier.volume25en_US
dc.identifier.wosWOS:000366601700015en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofLupusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.subjectIncidenceen_US
dc.subjectPrevalenceen_US
dc.subjectEpidemiologyen_US
dc.subjectRevised Criteriaen_US
dc.subjectPopulationen_US
dc.subjectClassificationen_US
dc.subjectAgeen_US
dc.subjectManifestationsen_US
dc.subjectValidationen_US
dc.subjectNephritisen_US
dc.titleThe incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu